TBIO.jpg
Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
12 sept. 2019 16h05 HE | Translate Bio, Inc.
--  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy 
19 juin 2019 07h00 HE | Sorrento Therapeutics, Inc.
“CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations○ Clinical...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations
16 avr. 2019 09h00 HE | Sorrento Therapeutics, Inc.
Cannabidiol (CBD) material from virtually THC-free (<0.3%) hemp plants sourcesExcipients on the FDA approved GRAS (Generally Regarded As Safe) listWater soluble formulations with target...
Novacap to expand it
Novacap to expand its pharmaceutical offering in the U.S. with the acquisition of PCI Synthesis
20 juin 2018 12h03 HE | PCI Synthesis; Novacap
LYON, France and NEWBURYPORT, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced today that it has signed an...
VBLogo.jpg
Vitality Biopharma Receives DEA Renewal for Cannabinoid Pharma Development Program
20 juin 2018 08h00 HE | Vitality Biopharma, Inc
LOS ANGELES, June 20, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid...
PCI Synthesis Celebr
PCI Synthesis Celebrates Key Milestones Including 4th Consecutive Year of Double-Digit Growth, 2 Commercial Approvals and a New Office in San Diego
27 févr. 2018 09h15 HE | PCI Synthesis
NEWBURYPORT, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEis), generic active pharmaceutical...
AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
27 févr. 2018 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies (OTC:AXIM) (“AXIM”), the world leader in cannabinoid research and development, today announced the first-ever successful execution...
PCI Synthesis Submit
PCI Synthesis Submits Patent for Synthesizing Azelaic Acid
30 janv. 2018 09h15 HE | PCI Synthesis
NEWBURYPORT, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
PCI Synthesis’ Ed Pr
PCI Synthesis’ Ed Price Joins SOCMA’s Board of Governors
11 janv. 2018 09h15 HE | PCI Synthesis
NEWBURYPORT, Mass., Jan. 11, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
PCI Synthesis Identi
PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2018
18 déc. 2017 09h15 HE | PCI Synthesis
NEWBURYPORT, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...